Ampudia-Mesias E - Search Results

1

SRPX Emerges as a Potential Tumor Marker in the Extracellular Vesicles of Glioblastoma.

Ampudia-Mesias E, El-Hadad S, Cameron CS, Wöhrer A, Ströbel T, Saydam N, Saydam O. Ampudia-Mesias E, et al. Cancers (Basel). 2022 Apr 14;14(8):1984. doi: 10.3390/cancers14081984. Cancers (Basel). 2022. PMID: 35454889 Free PMC article.

2

Extracellular-Vesicle-Based Cancer Panels Diagnose Glioblastomas with High Sensitivity and Specificity.

Mut M, Adiguzel Z, Cakir-Aktas C, Hanalioğlu Ş, Gungor-Topcu G, Kiyga E, Isikay I, Sarac A, Soylemezoglu F, Strobel T, Ampudia-Mesias E, Cameron C, Aslan T, Tekirdas E, Hayran M, Oguz KK, Henzler C, Saydam N, Saydam O. Mut M, et al. Among authors: ampudia mesias e. Cancers (Basel). 2023 Jul 26;15(15):3782. doi: 10.3390/cancers15153782. Cancers (Basel). 2023. PMID: 37568598 Free PMC article.

3

Treatment Combining CD200 Immune Checkpoint Inhibitor and Tumor-Lysate Vaccination after Surgery for Pet Dogs with High-Grade Glioma.

Olin MR, Ampudia-Mesias E, Pennell CA, Sarver A, Chen CC, Moertel CL, Hunt MA, Pluhar GE. Olin MR, et al. Among authors: ampudia mesias e. Cancers (Basel). 2019 Jan 24;11(2):137. doi: 10.3390/cancers11020137. Cancers (Basel). 2019. PMID: 30682795 Free PMC article.

4

Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.

Xiong Z, Ampudia-Mesias E, Shaver R, Horbinski CM, Moertel CL, Olin MR. Xiong Z, et al. Among authors: ampudia mesias e. Immunotherapy. 2016 Sep;8(9):1059-71. doi: 10.2217/imt-2016-0033. Immunotherapy. 2016. PMID: 27485078 Free PMC article.

5

[No title available]

[No authors listed] [No authors listed] PMID: 36784115

6

CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway.

Ampudia-Mesias E, Puerta-Martinez F, Bridges M, Zellmer D, Janeiro A, Strokes M, Sham YY, Taher A, Castro MG, Moertel CL, Pluhar GE, Olin MR. Ampudia-Mesias E, et al. Neurotherapeutics. 2021 Jul;18(3):1980-1994. doi: 10.1007/s13311-021-01038-1. Epub 2021 Apr 7. Neurotherapeutics. 2021. PMID: 33829411 Free PMC article.

7

Correction to: CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway.

Ampudia-Mesias E, Puerta-Martinez F, Bridges M, Zellmer D, Janeiro A, Strokes M, Sham YY, Taher A, Castro MG, Moertel CL, Pluhar GE, Olin MR. Ampudia-Mesias E, et al. Neurotherapeutics. 2021 Jul;18(3):2131. doi: 10.1007/s13311-021-01062-1. Neurotherapeutics. 2021. PMID: 33929711 Free PMC article. No abstract available.

8

CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy.

Xiong Z, Ampudia Mesias E, Pluhar GE, Rathe SK, Largaespada DA, Sham YY, Moertel CL, Olin MR. Xiong Z, et al. Among authors: ampudia mesias e. Clin Cancer Res. 2020 Jan 1;26(1):232-241. doi: 10.1158/1078-0432.CCR-19-2234. Epub 2019 Oct 17. Clin Cancer Res. 2020. PMID: 31624103

9

The OTX2 Gene Induces Tumor Growth and Triggers Leptomeningeal Metastasis by Regulating the mTORC2 Signaling Pathway in Group 3 Medulloblastomas.

Ampudia-Mesias E, Cameron CS, Yoo E, Kelly M, Anderson SM, Manning R, Abrahante Lloréns JE, Moertel CL, Yim H, Odde DJ, Saydam N, Saydam O. Ampudia-Mesias E, et al. Int J Mol Sci. 2024 Apr 17;25(8):4416. doi: 10.3390/ijms25084416. Int J Mol Sci. 2024. PMID: 38674001 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9 results

Search Page